Tesaro seeks $86.2M IPO, leading with PhIII rolapitant for chemo nausea
This article was originally published in Scrip
Tesaro Inc is testing the waters and trying to convince investors to buy into its $86.2 million initial public offering – all the while touting its experienced team of people who have previously shown they can get cancer drugs through the later stages of development. The firm has no marketed products or revenue, and is focused primarily on two in-licensed candidates (one in Phase III). More in-licensing is planned.